Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of lung adenocarcinoma
3.2.1.2 Advances in precision medicine and targeted therapies
3.2.1.3 Rising awareness and early detection programs
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of treatments
3.2.2.2 Adverse effects and safety concerns
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Pipeline analysis
3.7 Future market trends
3.8 Porter’s analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Surgery
5.3 Radiation therapy
5.4 Chemotherapy
5.5 Targeted therapy
5.6 Immunotherapy
5.7 Other treatment types
Chapter 6 Market Estimates and Forecast, By Stage of Disease, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Stage I & II
6.3 Stage III
6.4 Stage IV
Chapter 7 Market Estimates and Forecast, By End-use, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospitals
7.3 Specialty clinics
7.4 Other end-users
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 AbbVie Inc.
9.2 Amgen Inc.
9.3 AstraZeneca PLC
9.4 Boehringer Ingelheim International GmbH
9.5 Bristol-Myers Squibb Company
9.6 Celgene Corporation
9.7 Eli Lilly and Company
9.8 F. Hoffmann-La Roche Ltd
9.9 GlaxoSmithKline plc
9.10 Johnson & Johnson Services, Inc.
9.11 Merck & Co., Inc.
9.12 Novartis AG
9.13 Pfizer Inc.
9.14 Sanofi S.A.
9.15 Takeda Pharmaceutical Company Limited
